Prospera Financial Services Inc Has $85,000 Position in Sanofi (NASDAQ:SNY)

Prospera Financial Services Inc reduced its stake in Sanofi (NASDAQ:SNYGet Rating) by 18.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,689 shares of the company’s stock after selling 374 shares during the period. Prospera Financial Services Inc’s holdings in Sanofi were worth $85,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in SNY. Tcwp LLC acquired a new stake in Sanofi during the 1st quarter worth approximately $36,000. US Bancorp DE boosted its position in Sanofi by 10.1% during the 2nd quarter. US Bancorp DE now owns 85,318 shares of the company’s stock worth $4,268,000 after buying an additional 7,809 shares during the period. Veriti Management LLC boosted its position in Sanofi by 117.4% during the 2nd quarter. Veriti Management LLC now owns 30,775 shares of the company’s stock worth $1,540,000 after buying an additional 16,621 shares during the period. Assetmark Inc. boosted its position in Sanofi by 188.2% during the 2nd quarter. Assetmark Inc. now owns 37,394 shares of the company’s stock worth $1,871,000 after buying an additional 24,420 shares during the period. Finally, Ritholtz Wealth Management lifted its position in shares of Sanofi by 35.2% in the 2nd quarter. Ritholtz Wealth Management now owns 18,483 shares of the company’s stock worth $925,000 after purchasing an additional 4,810 shares during the period. 10.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sanofi from €90.00 ($92.78) to €85.00 ($87.63) and set a “hold” rating on the stock in a research report on Wednesday, September 7th. Credit Suisse Group boosted their price target on shares of Sanofi from €105.00 ($108.25) to €110.00 ($113.40) and gave the stock an “outperform” rating in a research report on Friday, July 22nd. Cheuvreux downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Wednesday, August 24th. StockNews.com initiated coverage on shares of Sanofi in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Finally, JPMorgan Chase & Co. boosted their price target on shares of Sanofi from €105.00 ($108.25) to €115.00 ($118.56) in a research report on Monday, August 1st. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Sanofi Stock Performance

Shares of SNY stock opened at $43.55 on Wednesday. The firm has a market capitalization of $110.40 billion, a PE ratio of 15.78, a price-to-earnings-growth ratio of 1.05 and a beta of 0.59. The firm has a fifty day simple moving average of $40.95 and a two-hundred day simple moving average of $42.64. The company has a current ratio of 1.29, a quick ratio of 0.34 and a debt-to-equity ratio of 0.22. Sanofi has a 12 month low of $36.91 and a 12 month high of $58.10.

Sanofi Company Profile

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

See Also

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.